autologous monocytes + interferon gamma-1b + peginterferon beta-1a

This is a combination therapy consisting of three components: - **Autologous monocytes** are immune cells derived from the patient's own blood, often used in cell-based immunotherapies to modulate or stimulate immune responses. - **Interferon gamma-1b** is a recombinant cytokine that activates macrophages and enhances antigen presentation, used primarily for chronic granulomatous disease and severe malignant osteopetrosis. It acts as an immunomodulator by binding to the interferon gamma receptor, leading to increased expression of major histocompatibility complex (MHC) molecules and other immune-stimulating effects. - **Peginterferon beta-1a** is a pegylated form of interferon beta-1a, an immunomodulatory agent approved for relapsing forms of multiple sclerosis. It reduces inflammation by decreasing antigen presentation and T-cell proliferation, modifying cytokine expression, and restoring suppressor function[3][5][6][7]. The combination suggests an investigational or experimental approach aimed at leveraging both cellular (monocyte-based) and cytokine-mediated (interferons) modulation of the immune system. There is no evidence this specific triple combination has been approved or widely studied as a single product; each component has distinct mechanisms but all act on various aspects of immune regulation.